(ADTN) Adtran won IP service contract from Verizon.
(ASVI) ASV $0.09 EPS vs $0.11e.
(BNT) Bentley Pharma announced approval of its generic oncology product in Spain.
(CAKE) Cheesecake Factory announced an additional 10M shares for a buyback plan.
(CBMX) CombiMatrix group’s subsidiary, CombiMatrix Molecular Diagnostics, has entered into a partnership with The Centre for Applied Genomics in Toronto, Canada.
(CGEN) Compugen announces a second agreement with Biosite (BSTE) for the development and commercialization of immunoassay diagnostic products.
(CHINA) CDC entered new gaming platform JV in China.
(CHS) Chico’s FAS traded up 4% after earnings and guidance in-line.
(CRXL) Crucell gets another $5M for TB research.
(CVTX) CV Therapeutics down over 20% on bad drug data.
(ENCY) Encysive Pharma’s THELIN receives Australian marketing approval.
(FCS) Fairchild Semi reiterated guidance of -3% to -6% for revenues.
(FLR) Fluor awarded $462M Oxiana contract to develop Australia’s Prominent Hill copper-gold project.
(FRN) Friendly’s Ice Cream hired Goldman Sachs to explore strategic alternatives and enhance shareholder value.
(GOOG) Google up 1% on upgrade.
(HLYS) Heelys trading down 3% after beating earnings estimates because it won’t give forward guidance other than 20-25% growth.
(HOFF) Horizon Offshore signed a US Northeast contract and announced $300M in backlog.
(HYC) Hypercom $0.05 EPS vs $0.02e; raised guidance.
(IRBT) iRobot gets $2.8M order for 22 units in Germany.
(IW) Imageware in PEM agreement with Honeywell.
(KAI) Kadant has an $18M order in Asia and $10M more pending.
(MOVI) Movie Gallery is paying about $10M to acquire MovieBeam.
(PNY) Piedmont $0.94 EPS vs $0.98e.
(PTA) Penn Treaty filed its annual documents.
(PTNX) Printronics in expanded distribution pact with Ingram Micro.
(SPW) SPX Corp announced sale of Contech business for $146M cash.
(TAYC) Taylor Capital has increased its bad loan and delinquent loan amounts previously offered.
(WVCM) Wavcom Wireless in pact with Peugeot.
(ZGEN) Zymogentics said t hat the FDA will not require additional Phase III clinical trials with recombinant human Thrombin administered by a spray device.
Jon C. Ogg
March 7, 2007
Top Gaining Stocks
Top Losing Stocks